Compassionate use
Hansa is committed to leveraging our unique immunomodulating technology platform to develop innovative, lifesaving, and life-altering treatments for patients with rare immunologic conditions. As we take our commitment to patients very seriously, Hansa shares your urgency as we strive to develop new treatments and complete the rigorous scientific and regulatory requirements. We firmly believe that conducting thorough clinical trials to evaluate safety and efficacy, and securing regulatory approval, is paramount to ensuring that our treatments reach as many patients as possible.
As a result, we are unable to offer a compassionate use program at this time without jeopardizing our ability to conduct the trials needed to gain timely regulatory approval and provide patients broad, equitable, and sustainable access. We believe the most appropriate way to access our investigational therapies is to participate in clinical trials assessed by regulatory entities across the globe. Completing our current and future clinical trials, with diligence and efficiency, remains the best path to potential regulatory approval and ensuring widespread access to our therapies.
Hansa will continue to evaluate the possibility of compassionate use and will update our policy if our position changes. Physicians seeking more information can contact medinfo@hansabiopharma.com. We anticipate acknowledging receipt of requests within 5 business days. For information regarding Hansa clinical trials, please visit:
clinicaltrials.gov